Tuesday, December 04, 2007

Promising new HIV-AIDS drug, 1st in new class, approved for Canadian market

From Canada East:
Health Canada has granted licence approval for a new HIV-AIDS drug, the first in a promising new class of medications.

Drug maker Merck Frosst says it has been given permission to bring Isentress to the Canadian market for treatment of HIV-positive people whose viruses are resistant to multiple other HIV drugs. AIDS expert Dr. Mark Wainberg says there is tremendous optimism about the drug in the community of HIV patients, doctors and researchers.

The drug's generic name is raltegravir.

It is the first in a new class of drugs known as integrase inhibitors to hit the global AIDS drug market; another drug, eltegravir, is in development by Gilead Sciences Inc. of Foster City, CA. ...more

No comments: